Jose M de la Torre Hernandez

Summary

Country: Spain

Publications

  1. de la Torre Hernandez J, Moreno R, Gonzalo N, Rivera R, Linares J, Veiga Fernandez G, et al. The Pt-Cr everolimus-eluting stent with bioabsorbable polymer in the treatment of patients with acute coronary syndromes. Results from the SYNERGY ACS registry. Cardiovasc Revasc Med. 2018;: pubmed publisher
    ..A total of 1008 patients have been included. Primary outcome was met in 3% (7% in SYNERGY TIDES-ACS arm, P superiority <0.01 and 6.3% in OPTIMAX TIDES-ACS arm, P superiority <0.01). ..
  2. de la Torre Hernandez J, Brugaletta S, Gomez Hospital J, Baz J, Perez de Prado A, Lopez Palop R, et al. Baseline Risk Stratification of Patients Older Than 75 Years With Infarction and Cardiogenic Shock Undergoing Primary Angioplasty. Rev Esp Cardiol (Engl Ed). 2018;: pubmed publisher
  3. de la Torre Hernandez J, Gorria G, de Prada J, Zueco J. Papillary muscle rupture: first report of this complication in a retrograde transfemoral aortic valve implantation. Catheter Cardiovasc Interv. 2011;78:647-9 pubmed publisher
    ..We found papillary muscle head calcification as an anatomical substrate that could facilitate this complication. ..
  4. de la Torre Hernández J, Oteo Domínguez J, Hernández F, García Camarero T, Abdul Jawad Altisent O, Rivero Crespo F, et al. Dual Antiplatelet Therapy for 6 Months vs 12 Months After New-generation Drug-eluting Stent Implantation: Matched Analysis of ESTROFA-DAPT and ESTROFA-2. Rev Esp Cardiol (Engl Ed). 2015;68:838-45 pubmed publisher
  5. de la Torre Hernández J, Tejedor P, Camarero T, Duran J, Lee D, Monedero J, et al. Early healing assessment with optical coherence tomography of everolimus-eluting stents with bioabsorbable polymer (synergy™) at 3 and 6 months after implantation. Catheter Cardiovasc Interv. 2016;88:E67-73 pubmed publisher
    ..2015 Wiley Periodicals, Inc. ..
  6. de la Torre Hernández J, Alfonso F, Martin Yuste V, Sánchez Recalde A, Jiménez Navarro M, Pérez de Prado A, et al. Comparison of paclitaxel and everolimus-eluting stents in ST-segment elevation myocardial infarction and influence of thrombectomy on outcomes. ESTROFA-IM study. Rev Esp Cardiol (Engl Ed). 2014;67:999-1006 pubmed publisher
    ..The lower risk of thrombosis with these stents could be more relevant in the absence of thrombectomy. ..
  7. request reprint
    de la Torre Hernandez J, Moreno R, Lee D, Garcia Del Blanco B, Sanmartín J, Garcia Blas S, et al. The routine use of surgical exposure approach for trans-femoral implantation of the balloon expandable aortic prosthesis is associated to a low rate of vascular complications. J Cardiovasc Surg (Torino). 2016;57:615-9 pubmed
    ..5% in patients with no complications (P=0.05). In this registry, the systematic use of a surgical exposure of the femoral artery for TAVR has been associated with a lower rate of vascular complications. ..
  8. de la Torre Hernandez J, Brugaletta S, Gomez Hospital J, Baz J, Perez de Prado A, Lopez Palop R, et al. Primary Angioplasty in Patients Older Than 75 Years. Profile of Patients and Procedures, Outcomes, and Predictors of Prognosis in the ESTROFA IM+75 Registry. Rev Esp Cardiol (Engl Ed). 2017;70:81-87 pubmed publisher
    ..Positive procedure-related predictors include shorter delay, use of radial access, bivalirudin, drug-eluting stents, and complete revascularization before discharge. ..
  9. de la Torre Hernandez J, Gomez Hospital J, Baz J, Brugaletta S, Perez de Prado A, Linares J, et al. Multivessel disease in patients over 75years old with ST elevated myocardial infarction. Current management strategies and related clinical outcomes in the ESTROFA MI+75 nation-wide registry. Cardiovasc Revasc Med. 2018;19:580-588 pubmed publisher
    ..Multivessel PCI was independent predictor of cardiac death and infarction with the best prognosis corresponding to those undergoing staged procedures. ..

More Information

Publications13

  1. de la Torre Hernandez J, Rumoroso J, Ojeda S, Brugaletta S, Cascon J, Ruisanchez C, et al. Angina and Ischemia at 2 Years With Bioresorbable Vascular Scaffolds and Metallic Drug-eluting Stents. ESTROFA Ischemia BVS-mDES Study. Rev Esp Cardiol (Engl Ed). 2018;71:327-334 pubmed publisher
    ..In addition, recurrent angina was similar in patients with BVS and mDES. The better functional status, assessed by means of SAQ and exercise performance, detected in patients receiving BVS should be confirmed in further studies. ..
  2. de la Torre Hernandez J, Garcia Camarero T. Intravascular Ultrasound for the Diagnosis and Treatment of Left Main Coronary Artery Disease. Interv Cardiol Clin. 2015;4:361-381 pubmed publisher
    ..IVUS-guided PCI with drug-eluting stents improves clinical outcomes, particularly in patients with distal left main disease. ..
  3. de la Torre Hernández J, Sadaba Sagredo M, Telleria Arrieta M, Gimeno de Carlos F, Sanchez Lacuesta E, Bullones Ramírez J, et al. Antithrombotic treatment during coronary angioplasty after failed thrombolysis: strategies and prognostic implications. Results of the RESPIRE registry. BMC Cardiovasc Disord. 2017;17:212 pubmed publisher
    ..No regimen proved predictive of mortality, but bivalirudin was related to more stent thrombosis. There was a high incidence of bleeding, associated with post-RA abciximab infusion and femoral access. ..
  4. de la Torre Hernandez J, Edelman E. From Nonclinical Research to Clinical Trials and Patient-registries: Challenges and Opportunities in Biomedical Research. Rev Esp Cardiol (Engl Ed). 2017;70:1121-1133 pubmed publisher
    ..Fortunately, challenges are always opportunities in disguise. ..